Mental Health Forum 2024: How the Mental Health Parity Act Affects Employers and Providers
February 28th 2024In a recent presentation featured at the Midwest Business Group on Health's Mental Health Forum, an expert shed light on the evolving landscape shaped by the Mental Health Parity and Addiction Treatment Act.
Read More
Study Finds Distinct Tumor Microenvironment Characteristics in HBV-Related HCC
February 28th 2024The analysis revealed that viral hepatocellular carcinoma (HCC) had a distinct microbial signature vs non-viral HCC, although only hepatitis B virus–related HCC showed a significantly diverse tumor microbiome.
Read More
Smartphone Tech Reveals Gait Differences in Duchenne Muscular Dystrophy
February 28th 2024Outside of a gait laboratory, this investigation compared gait pattern differences between children who have Duchenne muscular dystrophy (DMD) and their typically developing counterparts to gain more real-world data of DMD-associated gait characteristics.
Read More
What We’re Reading: Alabama IVF Ruling; UnitedHealth Antitrust Probe; Food as Medicine Initiative
February 28th 2024Survey highlights widespread opposition to Alabama's law restricting in vitro fertilization (IVF) access; investigation focuses on potential anticompetitive practices; Medicare weighs options for implementing a new program to deliver healthy meals to seniors with chronic conditions.
Read More
Review Highlights Potential for Bispecific Antibodies in DLBCL
February 28th 2024Investigators are optimistic about bispecific antibodies (BsAbs) for patients with diffuse large B-cell lymphoma (DLBCL), especially the possibility of combining different BsAbs with distinct targets for stronger treatment outcomes.
Read More
Nivolumab Continues to Produce Beneficial NSCLC Outcomes
February 27th 2024This most recent analysis from the CheckMate 9LA trial provides 4-year follow-up data on patients with stage IV metastatic/recurrent non–small cell lung cancer (NSCLC) randomized to treatment with nivolumab plus ipilimumab and chemotherapy vs chemotherapy alone.
Read More
The Promise of Frexalimab in MS Treatment: Part 1
February 26th 2024Patrick Vermersch, MD, PhD, joined The American Journal of Managed Care® for an interview on promising data from a phase 2 clinical trial on frexalimab in the treatment of multiple sclerosis (MS) and associated neurodegeneration.
Watch
What We’re Reading: Alabama IVF Ruling Impacts; Administrative Task Fees; Nursing Shortage Response
February 26th 2024Patients with cancer express shock and anxiety over the recent ruling by the Alabama Supreme Court regarding frozen embryos; doctors are beginning to charge fees for administrative tasks; some universities are implementing accelerated nursing programs to help with the shortage.
Read More
Health Equity and Access Weekly Roundup: February 24, 2024
February 24th 2024This week's news from the Center on Health Equity and Access discusses racial disparities in prostate cancer outcomes, the impact of access to cancer care on racial gaps in CLL/SLL outcomes, the effects of 340B programs on drug pricing and health care disparities, the role of mental illness in maternal mortality rates, and racial bias and diagnosis disparities in bipolar disorder.
Read More
Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma
February 23rd 2024The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows a dosing frequency of 1.5 mg/kg every 2 weeks.
Read More
The House Democratic Women’s Caucus wrote a letter urging insurers to comply with both contraceptive coverage requirements and recent Biden administration guidance; several pharmacy chains are experiencing disruptions following a hack at Change Healthcare, UnitedHealth’s technology unit; the FDA said it is not planning to take a tougher stance against clinical trial reporting requirement noncompliance.
Read More
Part 3: Dr James Robinson on the Impact of 340B Programs and Drug Pricing Policies
February 23rd 2024In part 3 of our interview with James Robinson, PhD, MPH, he discusses the need for reforms to commercial insurance that reflect the changes to Medicare under the Inflation Reduction Act, how the 340B drug pricing program has veered widely from its original goals, and ongoing cost sharing struggles among patients, insurers, hospitals, and drug companies.
Watch